Market Place
Sourcing Support
Roche Unveils Data Behind BTK Inhibitor`s Phase 3 MS Win
09 Feb 2026 //
FIERCE BIOTECH
Genentech`s Fenebrutinib Reduces Disability Progression
07 Feb 2026 //
PHARMIWEB
Roche`s Fenebrutinib Reduces Disability Progression In Primary
07 Feb 2026 //
GLOBENEWSWIRE
Genentech Unveils Ocrevus, Fenebrutinib Data At ECTRIMS 2025
24 Sep 2025 //
BUSINESSWIRE
Roche Prsent Ocrevus And Fenebrutinib Data at ECTRIMS 2025
24 Sep 2025 //
GLOBENEWSWIRE
Roche`s Fenebrutinib Shows 2-Year Benefit in Relapsing Sclerosis
29 May 2025 //
GLOBENEWSWIRE
Roche`s Fenebrutinib Shows Promise In Multiple Sclerosis
04 Sep 2024 //
GLOBENEWSWIRE
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
04 Sep 2024 //
BIOSPACE
Genentech MS drug on partial US hold on liver enzyme elevations
05 Dec 2023 //
FIERCE BIOTECH
Late-breaking data for Roche™s fenebrutinib show reduction in lesions
13 Oct 2023 //
GLOBENEWSWIRE
Roche says new MS drug shown to reduce brain lesions
18 May 2023 //
REUTERS
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions
17 May 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.